What is the connection between HER-2 status and the selection of adriamycin-based therapy?
An interaction between HER-2 amplification and response to adriamycin-based therapies has been demonstrated. Specifically, HER-2 amplification is associated with improved response to intensified adriamycin-based chemotherapies. Clinical trials demonstrate that patients with HER-2 amplification may benefit from dose intensive adriamycin-based therapy based on disease-free and overall survival.